Cardio-oncology: where do we stand for in Belgium?

References

• Benjamin EJ, Muntner P, Alonso A, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, et al. Heart Disease and Stroke Statistics-2019 Update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403.
   PubMed Web of Science ®Google Scholar
• Timmis A, Townsend N, Gale CP, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020;41:12–85.
   PubMed Web of Science ®Google Scholar
• Koene RJ, Prizment AE, Blaes A, et al. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104–1114.
   PubMed Web of Science ®Google Scholar
• Vincent L, Leedy D, Masri SC, et al. Cardiovascular disease and cancer: is there increasing overlap? Curr Oncol Rep. 2019;21(6):1–13.
   Web of Science ®Google Scholar
• White MC, Holman DM, Boehm JE, et al. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46(3):S7–S15.
   Web of Science ®Google Scholar
• Morris PB, Ference BA, Jahangir E, et al. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology. J Am Coll Cardiol. 2015;66(12):1378–1391.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures. Atlanta, GA: American Cancer Society; 2014.
   Google Scholar
• Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123(3):327–334.
   Web of Science ®Google Scholar
• Stocks T, Van Hemelrijck M, Manjer J, et al. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension. 2012;59(4):802–810.
   Web of Science ®Google Scholar
• Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363(23):2211–2219.
   PubMed Web of Science ®Google Scholar
• Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98(13):920–931.
   PubMedGoogle Scholar
• Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med. 1999;341(15):1097–1105.
   PubMed Web of Science ®Google Scholar
• Lancellotti P, Galderisi M, Donal E, on behalf of the ESC Cardiac Oncology Toxicity Long-Term Registry Investigators, et al. Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC Heart Fail. 2017;4(3):312–318.
   Web of Science ®Google Scholar
• Mellitus D. A major risk factor for cardiovascular disease. Circulation. 1999;100:1132–1133.
   Web of Science ®Google Scholar
• Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 dia- betes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.
   PubMed Web of Science ®Google Scholar
• Stampfer M, Jahn JL. Partnerships for promoting prevention. Circulation. 2013;127(12):1267–1269.
   Web of Science ®Google Scholar
• Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256(20):2823–2828.
   PubMed Web of Science ®Google Scholar
• Alexopoulos CG, Blatsios B, Avgerinos A. Serum lipids and lipoprotein disorders in cancer patients. Cancer. 1987;60(12):3065–3070.
   Web of Science ®Google Scholar
• Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol. 2006;7(2):149–156.
   PubMed Web of Science ®Google Scholar
• Thune I, Furberg A-S. Physical activity and cancer risk: dose- response and cancer, all sites and site-specific. Med Sci Sports Exerc. 2001;33(6 Suppl):S530–S50.
   Web of Science ®Google Scholar
• Lancellotti P, Marechal P, Donis N, et al. – Inflammation, cardiovascular disease, and cancer: a common link with far-reaching implications. Eur Heart J. 2019;40:3910–3912.
   Web of Science ®Google Scholar
• Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–2247.
   PubMed Web of Science ®Google Scholar
• Lancellotti P, Anker SD, Donal E, et al. EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)—EURObservational Research Program of the European Society of Cardiology. Eur Heart J Cardiovasc Imaging. 2015;16(5):466–470.
   Web of Science ®Google Scholar
• Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–1582.
   PubMed Web of Science ®Google Scholar
• Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889–3897.
   PubMed Web of Science ®Google Scholar
• Herrmann J. From trends to transformation: where cardio-oncology is to make a difference. Eur Heart J. 2019;40(48):3898–3900.
   Web of Science ®Google Scholar
• Abdel-Qadir H, Thavendiranathan P, Austin PC, et al. Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. Eur Heart J. 2019;40(48):3913–3920.
   PubMed Web of Science ®Google Scholar
• Barros-Gomes S, Herrmann J, Mulvagh SL, et al. Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic. Cardio-Oncology. 2016;5(1):9.
   Google Scholar
• Lancellotti P, Suter TM, Lopez-Fernandez T, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J. 2019;40(22):1756–1763.
   PubMed Web of Science ®Google Scholar
• Plana J, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063–1093.
   PubMed Web of Science ®Google Scholar
• Lancellotti P, Nkomo VT, Badano LP, In oration with the European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance and the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14(8):721–740.
   PubMed Web of Science ®Google Scholar
• Lancellotti P, Moonen M, Galderisi M. Chimeric antigen receptor T-cells and cardiovascular toxicity: cause for concern? J Am Coll Cardiol. 2019;74(25):3109–3111.
   Web of Science ®Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37(36):2768–2801.
   PubMed Web of Science ®Google Scholar